The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment
Abstract
Heart disease accounts for approximately half of the deaths of patients with ESRD (1–3). In the past 5 yr, there has been increasing recognition of both coronary artery disease (CAD) and left ventricular hypertrophy (LVH) in ESRD patients, as these are the two typical presentations of heart disease in ESRD patients. It is also clear that many patients with chronic kidney disease (CKD) and a GFR of <60 ml/min are at risk for heart disease; many of these patients succumb to heart disease before reaching dialysis (4–6). This review includes a brief overview of the problem, a discussion of CAD and LVH, and an examination of the benefits of reducing BP and proteinuria on both the heart and the kidney and concludes with a brief section on treatment options for individuals with this disorder. Overview of the Problem of Cardiovascular Disease in Patients with Kidney Disease A growing awareness of heart disease in individuals with kidney disease as a major public health concern has increased sharply because of the revelation that there are millions of Americans with reduced kidney function (2). This fact, coupled with the understanding that many individuals with CKD do not reach dialysis because they die of heart disease (6), has expanded the concern about heart disease in both patients with CKD and patients with ESRD. Of interest is that whereas many superb prospective, randomized clinical trials have defined the scope of the appropriate therapy for heart disease in patients with normal kidney function, relatively few trials have addressed the issue in patients with kidney disease. Thus, the literature on cardiovascular disease (CVD) has focused on individuals without kidney disease, and guidelines regarding the management of heart disease in patients with ESRD in CKD, therefore, are largely opinion based (7). The two clinical presentations of heart disease in patients with kidney disease are atherosclerotic vascular disease (particularly CAD) and LVH. Atherosclerosis has been known to be a particular problem in patients with ESRD for >25 yr since Lindner et al. (8) hypothesized that there was accelerated atherogenesis in patients with ESRD. In the Lindner study, 60% of a cohort who underwent dialysis for 6.5 yr died and 14 of these deaths were attributed to complications of atherosclerosis. Subsequent postmortem and angiographic studies confirmed that the prevalence of atherosclerosis is increased dramatically in patients who are on dialysis when compared with age-matched individuals without kidney impairment (9–13). Of note, this increase in atherosclerosis and, in particular, CAD is progressive over a range of reduced GFR. This has been shown by Anavekar et al. (5) and by Beddhu et al. (14). The major increase in risk for heart disease and death occurs at a GFR of <50 to 60 ml/min (5,14) (Figure 1). A major problem with the issue of coronary disease is that in many patients, there is a high burden of coronary disease despite that the patient is asymptomatic. In a recent study by deFilippi et al. (15), 44% of a large cohort of asymptomatic hemodialysis patients had significant coronary disease. This was confirmed recently by Ohtake et al. (16), who showed that coronary disease (defined as >50% stenosis in the coronary artery) was present in as many as 53% of a cohort of asymptomatic dialysis patients. A second presentation of heart disease in this patient population is LVH. It is particularly important to understand this disorder in dialysis patients because as many as 80% of an incident dialysis population will have LVH as they begin dialysis (17). Individuals with LVH have both eccentric and concentric hypertrophy (18,19). Eccentric hypertrophy results from volume overload leading to cardiac myocyte dropout; LVH is characterized by a myocyte to arteriolar capillary mismatch. Concentric hypertrophy typically is the result of hypertension and increased afterload and is exacerbated by anemia, hyperparathyroidism, and high angiotensin II concentrations. Eccentric and concentric hypertrophy are relatively equivalent in prevalence in dialysis patients. The dominant LV physiology that accompanies heart disease in patients who are on dialysis is that of diastolic dysfunction (17,19). This physiology results in a sharp increase in LV diastolic pressure with modest increments in LV volume; the implication of the physiology is that patients have a lower threshold to pulmonary edema under these circumstances (Figure 2). Conversely, patients who undergo ultrafiltration on dialysis can experience a sharp fall in LV diastolic pressure under circumstances of a modest volume reduction, thereby risking sudden hypotension and hemodynamic instability. Patients with LVH also often have a reduction in systolic function, and the presence of this abnormality also exposes patients to the risk for sudden CV death (20). Cardiac arrhythmias and cardiac deaths are common in dialysis patients of all ages but are particularly problematic in
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Self-citationPfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Cited by
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Ronco, C., Haapio, M., House, A. A., Anavekar, N., & Bellomo, R. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.051 · Cited by 1,883
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
European guidelines on cardiovascular disease prevention in clinical practice: Executive summary
Graham, I. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.08.024 · Cited by 722
Heart failure and kidney dysfunction: epidemiology, mechanisms and management
Schefold, J. C., Filippatos, G., Hasenfuss, G., Anker, S. D., & von Haehling, S. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.113 · Cited by 671
Metadata
- Authors
- Berl, T., & Henrich, W.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2006-01
- Volume
- 1
- Issue
- 1
- Pages
- 8-18
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2130771083
- Cited by
- 201
- References
- 17
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment. https://app.cochat.ai/papers/10.2215/cjn.00730805
- The paper
- Berl, T., & Henrich, W. (2006). Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.00730805
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.